Formulation optimization and in situ absorption in rat intestinal tract of quercetin-loaded microemulsion

被引:139
作者
Gao, Yan [1 ]
Wang, Yuqiang [1 ]
Ma, Yukun [2 ]
Yu, Aihua [1 ]
Cai, Fengqun [1 ]
Shao, Wei [1 ]
Zhai, Guangxi [1 ]
机构
[1] Shandong Univ, Coll Pharm, Dept Pharmaceut, Jinan 250012, Peoples R China
[2] Second Peoples Hosp Jinan, Dept Pharm, Jinan 250001, Peoples R China
关键词
Microemulsion; Quercetin; Simplex lattice mixture design; DRUG-DELIVERY SYSTEM; LYMPHATIC TRANSPORT; O/W MICROEMULSION; DESIGN; BIOAVAILABILITY; PERMEABILITY; PERFUSION; DOXORUBICIN; MEMBRANE; RELEASE;
D O I
10.1016/j.colsurfb.2009.03.005
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
A new microemulsion system has been developed to increase the solubility and oral absorption of quercetin, a poorly water-soluble drug. The formulation of quercetin-loaded microemulsion was optimized by a simplex lattice experiment design. The optimized microemulsion formulation consisted of oil (7%, w/w), surfactant (48%, w/w), and cosurfactant (45%, w/w). Under this condition, the mean droplet diameter of microemulsion was 38.9 nm and solubility of quercetin in the microemulsion was 4.138 mg/ml. The in situ absorption property of quercetin-loaded microemulsion in rat intestine was studied and the results showed there was significant difference in absorption parameters such as K-a, t(1/2) and uptake percentages between microemulsion and micelle solution containing quercetin. The study on absorption percentage in different regions of rat intestine attested that the colon had the best permeability, followed by ileum. duodenum in order. It can be concluded that microemulsion can improve the solubility and oral absorption of quercetin, a poorly water-soluble drug. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:306 / 314
页数:9
相关论文
共 46 条
  • [21] HU YQ, 1996, J CHIN PHARM U, V27, P355
  • [22] Mixture experiments with the oil phase of parenteral emulsions
    Jumaa, M
    Kleinebudde, P
    Muller, BW
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 1998, 46 (02) : 161 - 167
  • [23] Microemulsion formulation for enhanced absorption of poorly soluble drugs - I. Prescription design
    Kawakami, K
    Yoshikawa, T
    Moroto, Y
    Kanaoka, E
    Takahashi, K
    Nishihara, Y
    Masuda, K
    [J]. JOURNAL OF CONTROLLED RELEASE, 2002, 81 (1-2) : 65 - 74
  • [24] Disposition of the flavonoid quercetin in rats after single intravenous and oral doses
    Khaled, KA
    El-Sayed, YM
    Al-Hadiya, BM
    [J]. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2003, 29 (04) : 397 - 403
  • [25] Intestinal lymphatic transport of halofantrine occurs after oral administration of a unit-dose lipid-based formulation to fasted dogs
    Khoo, SM
    Shackleford, DM
    Porter, CJH
    Edwards, GA
    Charman, WN
    [J]. PHARMACEUTICAL RESEARCH, 2003, 20 (09) : 1460 - 1465
  • [26] Improved solubilization of carbamazepine and structural transitions in nonionic microemulsions upon aqueous phase dilution
    Kogan, Anna
    Aserin, Abraham
    Garti, Nissim
    [J]. JOURNAL OF COLLOID AND INTERFACE SCIENCE, 2007, 315 (02) : 637 - 647
  • [27] Microemulsions as transdermal drug delivery vehicles
    Kogan, Anna
    Garti, Nissim
    [J]. ADVANCES IN COLLOID AND INTERFACE SCIENCE, 2006, 123 (369-385) : 369 - 385
  • [28] Application of chemometrics methods with kinetic constraints for estimation of rate constants of second order consecutive reactions
    Kompany-Zareh, Mohsen
    Khoshkam, Maryam
    [J]. ANALYTICAL SCIENCES, 2008, 24 (05) : 637 - 645
  • [29] Validated HPLC analytical method with programmed wavelength UV detection for simultaneous determination of DRF-4367 and Phenol red in rat in situ intestinal perfusion study
    Kumar, TRS
    Chawla, S
    Nachaegari, SK
    Singh, SK
    Srinivas, NR
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2005, 38 (01) : 173 - 179
  • [30] Fast- and slow-release tablets for oral administration of flavonoids: Rutin and quercetin
    Lauro, MR
    Torre, ML
    Maggi, L
    De Simone, F
    Conte, U
    Aquino, PR
    [J]. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2002, 28 (04) : 371 - 379